The study analyzed 207 patients who had total knee replacements for chronic forms of arthritis. Some patients received a Novocain-type drug, the traditional option, and others were given the newer local anesthesia.
Here are four key facts:
1. The findings indicated both drugs were equally effective at alleviating pain, which is important as patients who experience severe pain recover much more slowly.
2. John Matsinger, MD, chief clinical officer, Virtua, said, “This study exemplifies how Virtua continues to provide the best quality and most cost-effective care. The JRI team found that reducing and managing pain after knee replacement is possible with a medication that is both affordable and effective.”
3. The American Association of Hip and Knee Surgeons granted Virtua’s six-person research team a national award on Nov. 7.
4. The team was selected as one of 60 teams to be recognized from 1,300 submissions for the award.
More articles on spine:
8 things for spine surgeons to know for Thursday — Nov. 19, 2015
ProDisc-C vs. spinal fusion: Which has better results? 5 key notes
Dr. Patrick Ganzer honored for VNS therapy research: 5 observations
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.